V
Vincent C. O. Njar
Researcher at University of Maryland, Baltimore
Publications - 154
Citations - 10648
Vincent C. O. Njar is an academic researcher from University of Maryland, Baltimore. The author has contributed to research in topics: Prostate cancer & Androgen receptor. The author has an hindex of 42, co-authored 146 publications receiving 9790 citations. Previous affiliations of Vincent C. O. Njar include Saarland University & University of Maryland Marlene and Stewart Greenebaum Cancer Center.
Papers
More filters
Journal ArticleDOI
Synthesis of novel C17 steroidal carbamates. Studies on CYP17 action, androgen receptor binding and function, and prostate cancer cell growth.
TL;DR: The synthesis of a series of novel C17 steroidal carbamates with carbamate moiety at C17 allowed tight binding of the synthesized compounds to both wild-type (wt-) and mutated AR, and the compounds were found to have a dual effect, stimulating transcription at low concentrations while almost fully blocking it at the higher concentrations tested.
Journal ArticleDOI
Novel 10β-aziridinyl steroids; inhibitors of aromatase
TL;DR: Spectroscopic studies with microsomal aromatase preparations indicate that the inhibition process involves binding of aziridine nitrogen to the heme-iron of the enzyme.
Journal ArticleDOI
MS-275 synergistically enhances the growth inhibitory effects of RAMBA VN/66-1 in hormone-insensitive PC-3 prostate cancer cells and tumours
TL;DR: The mechanism of action of the combination of agents is DNA damage-induced p21 activation, resulting in inhibition of the Cdc2/cyclin B complex and accumulation of cells in G2/M phase, suggesting that VN/66-1 or its combination with MS-275 may be a novel therapy for the treatment of prostate carcinoma.
Journal ArticleDOI
Galeterone and The Next Generation Galeterone Analogs, VNPP414 and VNPP433-3β Exert Potent Therapeutic Effects in Castration-/Drug-Resistant Prostate Cancer Preclinical Models In Vitro and In Vivo.
Andrew K. Kwegyir-Afful,Senthilmurugan Ramalingam,Vidya P. Ramamurthy,Puranik Purushottamachar,Francis N. Murigi,Tadas S. Vasaitis,Weiliang Huang,Maureen A. Kane,Yuji Zhang,Yuji Zhang,Nicholas P. Ambulos,Sudhir Tiwari,Pratima Srivastava,Ivo Nnane,Arif Hussain,Arif Hussain,Yun Qiu,Yun Qiu,David J. Weber,Vincent C. O. Njar +19 more
TL;DR: Findings show that targeting AR/AR-V7 and Mnk1/2 for degradation represents an effective therapeutic strategy for PC/CRPC treatment and supports further development of VNPP433-3β towards clinical investigation.
Journal ArticleDOI
Transcriptome profiling reveals that VNPP433‐3β, the lead next‐generation galeterone analog inhibits prostate cancer stem cells by downregulating epithelial–mesenchymal transition and stem cell markers
E. Thomas,Retheesh S. Thankan,Puranik Purushottamachar,Wei-Lun Huang,Maureen A. Kane,Yuji Zhang,N P Ambulos,David J. Weber,Vincent C. O. Njar +8 more
TL;DR: